1202186-71-7

Basic information

• Product Name: 1-Cyclohexene-1-carboxaldehyde, 2-(4-chlorophenyl)-5,5-diMethyl-
• Synonyms: 1-Cyclohexene-1-carboxaldehyde, 2-(4-chlorophenyl)-5,5-diMethyl-;2-(4-Chlorophenyl)-5,5-dimethylcyclohex-1-ene-1-carboxaldehyde;2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexene-1-carboxaldehyde;4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-carbaldehyde;2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-ene-1-carbaldehyde;EOS-62144;2-(4-chlorophenyl)-5,5-dimethylcyclohexene-1-carbaldehyde
• CAS NO: 1202186-71-7
• Molecular Formula: C₁₅H₁₇ClO
• Molecular Weight: 248.74788
• Mol File: 1202186-71-7.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-Cyclohexene-1-carboxaldehyde, 2-(4-chlorophenyl)-5,5-diMethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Cyclohexene-1-carboxaldehyde, 2-(4-chlorophenyl)-5,5-diMethyl-(1202186-71-7)
• EPA Substance Registry System: 1-Cyclohexene-1-carboxaldehyde, 2-(4-chlorophenyl)-5,5-diMethyl-(1202186-71-7)

Safety Data

• Hazardous Substances Data: 1202186-71-7(Hazardous Substances Data)

Usage

Classification

Broad-spectrum antibiotic This term indicates that the compound is effective against a wide range of microorganisms, including both Gram-negative and Gram-positive bacteria, as well as some anaerobic bacteria.

Mechanism of action

Inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit This explains how the compound works to stop the growth of bacteria by interfering with their ability to produce proteins, which are essential for their survival and reproduction.

Common uses

Treatment of serious infections such as typhoid fever, bacterial meningitis, and rickettsial infections This list provides examples of the types of infections that the antibiotic is typically used to treat, which are often severe and life-threatening.

Upstream product

• 1202186-75-1 (2E)-1-(4-chlorophenyl)-4,4-dimethyl-2-(((triisopropylsilyl)oxy)methylene)cyclohexanol 
• 1202186-79-5 1-(4-chlorophenyl)-2-(diethoxymethyl)-4,4-dimethylcyclohexanol 
• 105854-65-7 2-chloro-5,5-dimethylcyclohex-1-enecarbaldehyde 
• 1679-18-1 4-Chlorophenylboronic acid 
• 64230-02-0 (E)-2-(hydroxymethylene)-4,4-dimethylcyclohexan-1-one 
• 873-77-8 (4-chlorphenyl)magnesium bromide 
• 1053265-66-9 2-bromo-5,5'-bis-methylcyclohex-1-enylcarbaldehyde 
• 4255-62-3 4,4-dimethylcyclohexane-1-one 
• 1027345-21-6 (4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methanol 

Downstream Products

• 1065604-70-7 ethyl 4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl) benzoate 
• 1274804-96-4 1-[2-(4-chloro-phenyl)-5.5-dimethyl-cyclohex-1-enylmethyl]-piperidin-4-one 
• 1274802-46-8 N-{7-[2-(4-chlorobiphenyl)-5,5-dimethylcyclohex-1-enylmethyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl}-4-((R)-3-morpholin-4-yl-1-phenylsulfanylmethyl-propylamino)-3-trifluoromethanesulfonylbenzenesulfonamide 
• 1027345-21-6 (4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methanol 
• 1027345-22-7 6-(bromomethyl)-4'-chloro-4,4-dimethyl-2,3,4,5-tetrahydro-1,1'-biphenyl 
• 1044598-91-5 4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoic acid 

Relevant articles and documents

CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS

The disclosure includes compounds of Formula (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1 Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

SULFONAMIDES AS INHIBITORS OF BCL-2 FAMILY PROTEINS FOR THE TREATMENT OF CANCER

The present invention includes novel compound and methods of treating a disease or disorder by antagonizing Bcl-2 family proteins, particularly compounds of Formula (I) or pharmaceutically acceptable salt thereof, as well as methods of treating a disease,